Altimmune, Inc. (ALT)
Market Cap | 439.60M |
Revenue (ttm) | 20,000 |
Net Income (ttm) | -90.24M |
Shares Out | 81.11M |
EPS (ttm) | -1.25 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,679,968 |
Open | 5.39 |
Previous Close | 5.42 |
Day's Range | 5.34 - 5.57 |
52-Week Range | 3.55 - 11.16 |
Beta | 0.57 |
Analysts | Strong Buy |
Price Target | 21.00 (+287.45%) |
Earnings Date | May 13, 2025 |
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. [Read more]
Financial Performance
In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 287.45% from the latest price.
News

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in ...

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, alt...

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...

Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Execut...

Altimmune Announces First Quarter 2025 Financial Results and Business Update
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Di...

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial...

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and c...

Altimmune to Participate in the Citizens Life Sciences Conference
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will...

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market ...

Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

Altimmune to Host Virtual R&D Day on March 13, 2025
Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA Program to Feature Presentations from Renowne...

Altimmune to Participate in the Leerink Global Healthcare Conference
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will...

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock...

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief E...

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two addition...

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-ye...

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202...

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase ...
Final Trade: WST, BTC, GLD, ALT
The final trades of the day with the Fast Money traders.

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti...

Altimmune Could Find A Partner For Its Phase 3 Exercise
ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while ...

Altimmune Added to Nasdaq Biotechnology Index
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index ...